\
&
Contact us
\
&
Contact us
Published on | 2 years ago
ProgrammesThe scientific institutions and companies located in Flanders succeed in acquiring a growing budget from the European Framework Programmes. Flanders, as a small region, clearly punches above its weight in this internationally competitive environment. This comes out of a new report recently published by EWI, the Departement of Economy, Science & Innovation.
The report shows that 2 of the 5 Flemish universities are in the top 5 of most succesful participants in Europe. It also indicates that, based on the return compared to number of inhabitants, Flemish participation is in 4th place in Horizon 2020 and, with the data already available, currently in the 8th place for Horizon Europe.
The report also shows that Flanders scores well in the field of fundamental and strategic basic research. For applied research, Flanders scores highly in the areas of ICT, health, food and the bioeconomy. 'Culture, Creativity and Inclusive Society' can also count on special interest and very large participation.
Horizon Europe's major innovation is the introduction of Missions. In these missions, Flanders mainly has a large share of participation and budget in the Soil Mission & Ocean Mission.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
